Pharma Focus Asia

Dipharma Francis S.r.l. completes acquisition of Kalexsyn, Inc.

Friday, May 18, 2018

Dipharma Francis S.r.l., a leading European manufacturer of Active Pharmaceutical Ingredients, is pleased to communicate that it has completed its previously announced acquisition of Kalexsyn, Inc. (Kalexsyn), a world-class Contract Research Organization (CRO) providing chemistry services to the biotechnology and pharmaceutical industry.

Pursuant to an agreement dated March 19, 2018, Dipharma has acquired all of the issued and outstanding shares of Kalexsyn through its American subsidiary Dipharma, Inc.

Kalexsyn, based in Kalamazoo, Michigan (USA), was founded in 2003 and provides chemistry services that support the drug discovery and development activities of their customers.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024